Ye et al. optimized the binding affinity of antibodies 42A1 (approximately 2.6 fold) and I4A3 (approximately 3.7 fold) to target the liver cancer antigen glypican-3 and severe acute respiratory syndrome coronavirus 2, respectively, through single mutations in the CDRs [24]. This evidence concerns the gene GPC3 and liver cancer.